A biotechnology company firmly on the radar is Cara Therapeutics (NASDAQ:CARA). The US-based drug developer was recently successful in its trialing of lead candidate Korsuva. At the end of May, CARA stock popped as the first of two pivotal studies came back yielding great results.
Here’s what we know.
CARA Stock Reacts to Korsuva TrialFirst off, investors need to understand what Korsuva aims to treat. Chronic kidney disease affects approximately 14% of Americans, with nearly 119,000 losing kidney function annually. A result of this is that a vast number of patients are put ...
Read The Full Article On MicroSmallCap.com
Get early insight on hidden secret gems on MicroSmallCap. Follow Crypto, Mining, Cannabis and Energy stocks and get free research reports here.
All content provided by MicroSmallCap is subject to our Terms Of Use and Disclaimer.